Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: In vitro studies of potential co-medication interactions

British Journal of Pharmacology

Volumn 129, Issue 8, 2000, Pages 1655-1667

  Bohets, H ^a   Lavrijsen, K ^a   Hendrickx, J ^a   Van Houdt, J ^a   Van Genechten, V ^a   Verboven, P ^a   Meuldermans, W ^a   Heykants, J ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Cisapride; CYP2A6; CYP3A4; Drug drug interactions; Human liver microsomes; In vitro; Norcisapride; Pharmacokinetics; Prokinetic

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DRUG DERIVATIVE; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MIBEFRADIL; MICONAZOLE; NEFAZODONE; RITONAVIR; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG INTERACTION; DRUG METABOLISM; GASTROINTESTINAL MOTILITY; HUMAN; IN VITRO STUDY; LIVER MICROSOME; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0034002752     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703246     Document Type: Article

References (54)

1. BACK, D.J., STEVENSON, P. & TJIA, J.F. (1989). Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinylestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br. J. Clin. Pharmacol., 28, 166-170.
2. BATEMAN, D.N. (1986). The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur. J. Clin. Pharmacol., 30, 205-208.
3. BEDFORD, T.A. & ROWBOTHAM, D.J. (1996). Cisapride drug interactions of clinical significance. Drug Safety, 15, 167-175.
4. BERTHOU, F., RATANASAVANH, D., RICE, C., PICARD, D., VOIRIN, T. & GUILLOUZO, A. (1989). Comparison of caffeine metabolism by slices, microsomes and hepatocyte cultures from adult human liver. Xenobiotica, 19, 401-417.
5. BLATCHFORD, N.R. (1988). The pharmacokinetics of oral and topical ketoconazole. In: Seborrhoeic dermatitis and dandruff a fungal disease. Shuster, S and Blatchford, N. (eds). Royal Society of Medicine Services International Congress and Symposium Series, Shuster S, Blatchford, N. (eds). 1988; 132, 29-34.
6. BRIAN, W.R., SARI, M.A., IWASAKI, M., SHIMADA, T., KAMINSKY, L.S. & GUENGERICH, F.P. (1990). Catalytic activities of human liver cytochrome P-450IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry, 29, 11280-11292.
7. BROUWERS, J.R. (1992). Drug interactions with quinolone antibacterials. Drug Safety, 7, 268-281.
8. 4 receptors. Eur. J. Pharmacol., 205, 203-208.
9. CHIBA, K., KOBAYASHI, K., MANABE, K., TANI, M., KAMATAKI, T. & ISHIZAKI, T. (1993). Oxidative metabolism of omeprazole in human liver microsomes. Co-segregation with S-mephenytoin. J. Pharmacol. Exp. Ther., 266, 52-59.
10. CHIBA, M., HENSLEIGH, M., NISHIME, J.A., BALANI, S.K. & LIN, J.H. (1996). Role of cytochrome P-450 3A4 in human metabolism of MK-639, a potent HIV protease inhibitor. Drug Metab. Dispos., 24, 307-314.
11. CHING, M.S., BLAKE, C.L., GHABRIAL, H., ELLIS, S.W., LENNARD, M.S., TUCKER, G.T. & SMALLWOOD, R.A. (1995). Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochem. Pharmacol., 50, 833-837.
12. DANESHMEND, T.K. & WARNOCK, D.W. (1988). Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokinet., 14, 13-34.
13. 1 activity. Clin. Pharmacol. Ther., 45, 34-40.
14. DELAFORGE, M., JAOUEN, M. & MANSUY, D. (1983). Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Biochem. Pharmacol., 32, 2309-2318.
15. DUESCHER, R.J. & ELFARRA, A.A. (1993). Determination of p-nitrophenol hydroxylase activity of rat liver microsomes by high pressure liquid chromatography. Anal. Biochem., 212, 311-314.
16. GOLDSTEIN, J.A., FALETTO, M.B. & ROMKES-SPARKS, M. (1994). Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 33, 1743-1752.
17. GREIFF, J.M. & ROWBOTHAM, D. (1994). Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin. Pharmacokin., 27, 447-461.
18. GROSS, A.J., GOH, Y.D., ADDISON, R.S. & SHENFIELD, C.M. (1999). Influence of grapefruit juice on cisapride pharmacokinetics. Clin. Pharmacol. Ther., 64, 395-401.
19. GUENGERICH, P. & SHIMADA, T. (1991). Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol., 4, 391-407.
20. HOROWITZ, M., MADDOX, A., HARDING, P.E., MADDERN, G.J., CHATTERTON, B.E., WISHART, J. & SHEARMAN, D.J. (1987). Effect of cisapride on gastric and oesophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology, 93, 1899-1907.
21. 14C-cisapride. J. Labelled. Compd. Radiopharm., 24, 1493-1501.
22. KIRCH, W., JANISCH, H.D., OHNHAUS, E.E. & VAN PEER, A. (1989). Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther. Drug Monit., 11, 411-414.
23. KUMAR, G.N., RODRIGUES, A.D., BUKO, A.M. & DENISSEN, J.F. (1996). Cytochrome P-450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther., 277, 423-431.
24. LEE, H.S., JIN, C., PARK, J. & KIM, D.H. (1994). Modulation of cytochrome P450 activities by 7,8-benzoflavone and its metabolites. Biochem. Molec. Biol. Int., 34, 483-491.
25. LIN, J.H., CHIBA, M., BALANI, S.K., CHEN, I.-W., KWEI, G.Y.-S., VASTAG, K.J. & NISHIME, J.A. (1996). Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos., 24, 1111-1120.
26. LOWRY, O.H., ROSENBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
27. MCCALLUM, R.W., PRAKASH, C., CAMPOLI-RICHARDS, D.M. & GOA, K.L. (1988). Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs, 36, 652-681.
28. MEULDERMANS, W., VAN PEER, A., HENDRICKX, J., LAUWERS, W., SWYSEN, E., BOCKX, M., WOESTENBORGHS, R. & HEYKANTS, J. (1988). Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug. Metab. Dispos., 16, 403-409.
29. MILES, J.S., MCLAREN, A.W., FORRESTER, L.M., GLANCEY, M.J., LANG, M.A. & WOLF, C.R. (1990). Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem. J., 267, 365-371.
30. MILLER, G.L. (1959). Protein determination for large numbers of samples. Anal. Chem., 31, 964-971.
31. MINERS, J.O., SMITH, K.J., ROBSON, R.A., MCMANUS, M.E., VERONESE, M.E. & BIRKETT, D.J. (1988). Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol., 37, 1137-1144.
32. OMURA, T. & SATO, R. (1964). The carbon monoxide binding pigment of liver microsomes. II Solubilisation, purification and properties. J. Biol. Chem., 239, 2379-2385.
33. ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F.J. & TSUTSUI, M. (1996). Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681-693.
34. OTTON, S.V., WU, D., JOFFE, R.T., CHEUNG, S.W. & SELLERS, E.M. (1993). Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther., 53, 401-409.
35. PERITI, P., MAZZEI, T., MINI, E. & NOVELLI, A. (1992). Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokin., 23, 106-131.
36. PETER, R., BÖCKER, R., BEAUNE, P.H., IWASAKI, M., GUENGERICH, F.P. & YANG, C.S. (1990). Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIEI. Chem. Res. Toxicol., 3, 566-573.
37. PICHARD, L., FABRE, I., FABRE, G., DOMERGUE, J., SAINT AUBERT, B., MOURAD, G. & MAUREL, P. (1990). Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug. Metab. Dispos., 18, 595-606.
38. RAMIREZ, B. & RICHTER, J.E. (1993). Promotility drugs in the treatment of gastro-oesophageal reflux disease. Alimentary Pharmacol. Ther., 7, 5-20.
39. RILEY, R.J., ROBERTS, P., KITTERINGHAM, N.R. & PARK, B.K. (1990). Formation of cytotoxic metabolites from phenytoin, imipramine, desimipramine, amitryptiline and mianserin by mouse and human hepatic microsomes. Biochem. Pharmacol., 39, 1951-1958.
40. ROWBOTHAM, D.J., MILLIGAN, K. & MCHUGH, P. (1991). Effect of cisapride on morphine absorption after oral administration of sustained-release morphine. Br. J. Anaesth., 67, 421-425.
41. SHAW, P.M., BARNES, T.S. & CAMERON, D. (1989). Purification and characterisation of an anti-convulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism. Biochem. J., 263, 653-663.
42. SHULMAN, R.J. (1996). Cisapride and the attack of the P-450s. J. Pediatr. Gastroenterol. Nutr., 23, 395-397.
43. SUTTON, D., BUTLER, A.M., NADIN, L. & MURRAY, M. (1997). Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J. Pharmacol. Exp. Ther., 282, 294-300.
44. TASSANEEYAKUL, W., BIRKETT, D.J., VERONESE, M.E., MCMANUS. M.E., TUKEY, R.H., QUATTROCHI, L.C., GELBOIN, H.V. & MINERS, J.O. (1993). Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther., 265, 401-407.
45. THOMAS, A.R., CHAN, L.-N., BAUMAN, J.L. & OLOPADE, C.O. (1998). Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy, 18, 381-385.
46. UGES, D.R.A. (1996). Referentiewaarden van xenobiotica in humaan materiaal. Pham. Weekbl., 130, 180-204.
47. VAN HAARST, A.D., VAN T KLOOSTER, G.A.E., VAN GERVEN, J.M.A., SCHOENMAKER, R.C., VAN OENE, J.L., BURGGRAAF, J., COENE, M.C. & COHEN, A.F. (1998). The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin. Pharmacol. Ther., 64, 542-546.
48. VON MOLTKE, L.L., GREENBLATT, D.J., COURT, M.H., DUAN, S.X., HARMATZ, J.S. & SHADER, R.I. (1995). Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol., 15, 125-131.
49. VERLINDEN, M., REYNTJENS, A. & SCHUERMANS, V. (1988). Safety profile of cisapride. Progress in the treatment of gastrointestinal motility disorders: the role of cisapride. In Excerpta Medica. Ed. Johnson & Lux. pp. 30-36. Amsterdam.
50. WALKER, A.M., SZNEKE, P., WEATHERBY, L.B., DICKER, L.W., LANZA, L.L., LOUGHLIN, J.E., YEE, C.L. & DREYER, N. (1999). The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Amer. J. Med., 107, 356-362.
51. WARD, S. & BACK, D.J. (1993). Metabolism of gestodene in human liver cytosol and microsomes in vitro. J. Steroid. Biochem. Molec. Biol., 46, 235-243.
52. WISEMAN, L.R. & FAULDS, D. (1994). Cisapride: An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs, 47, 116-152.
53. WYSOWSKI, D.K. & BACSANYI, J. (1996). Cisapride and fatal arrhythmia. N. Engl. J. Med., 335, 290.
54. YUN, C.H., SHIMADA, T. & GUENGERICH, F.P. (1991). Purification and characterisation of human liver microsomal cytochrome P-450 2A6. Am. Soc. Pharmacol. Exp. Ther., 40, 679-685.